CYCLOPHOSPHAMIDE Drug Patent Profile

Which patents cover Cyclophosphamide, and when can generic versions of Cyclophosphamide launch?

Cyclophosphamide is a drug marketed by Alembic, Ani Pharms, Cipla, Eirgen, Hikma, Senores Pharms, Zydus Lifesciences, Amneal, Baxter Hlthcare, Epic Pharma Llc, Hainan Poly, Hengrui Pharma, Sagent Pharms Inc, Sunny, Xgen Pharms, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma Speclts, Nexus, Sandoz, and Roxane. and is included in twenty-six NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has eleven patent family members in nine countries.

The generic ingredient in CYCLOPHOSPHAMIDE is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cyclophosphamide

A generic version of CYCLOPHOSPHAMIDE was approved as cyclophosphamide by BAXTER HLTHCARE on May 21^st, 2008.

Summary for CYCLOPHOSPHAMIDE

International Patents:	11
US Patents:	3
Applicants:	21
NDAs:	26
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CYCLOPHOSPHAMIDE

Paragraph IV (Patent) Challenges for CYCLOPHOSPHAMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CYCLOPHOSPHAMIDE	Injection	cyclophosphamide	2 g/10 mL	212501	1	2023-01-17
CYCLOPHOSPHAMIDE	Injection	cyclophosphamide	500 mg/2.5 mL and 1 g/5 mL	212501	1	2022-03-07

US Patents and Regulatory Information for CYCLOPHOSPHAMIDE

CYCLOPHOSPHAMIDE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sunny	CYCLOPHOSPHAMIDE	cyclophosphamide	INJECTABLE;INJECTION	215089-003	Oct 26, 2023	AP	RX	No	No
Hengrui Pharma	CYCLOPHOSPHAMIDE	cyclophosphamide	INJECTABLE;INJECTION	204555-003	Oct 31, 2014	AP	RX	No	No
Dr Reddys	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	212501-002	Jul 30, 2020	AP	RX	Yes	Yes			Y
Sandoz	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	217150-003	Sep 12, 2023		RX	Yes	Yes

International Patents for CYCLOPHOSPHAMIDE

See the table below for patents covering CYCLOPHOSPHAMIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2017514924	シクロホスファミド液状濃縮物の製剤
South Korea	20170008252	사이클로포스파미드 액상 농축 제제 (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE)
China	106456654	环磷酰胺液体浓缩制剂 (Formulations of cyclophosphamide liquid concentrate)
World Intellectual Property Organization (WIPO)	2015171460

Investment Scenario, Market Dynamics, and Financial Trajectory for Cyclophosphamide

Last updated: February 3, 2026

Summary

Cyclophosphamide, a cornerstone chemotherapeutic and immunosuppressive agent, faces a complex landscape shaped by patent expirations, generic competition, regulatory shifts, and emerging oncology treatments. While its wide clinical use sustains revenue streams, market growth prospects are constrained by patent challenges and evolving treatment protocols. This report evaluates the current investment landscape, market drivers, financial trajectory projections, and strategic considerations for stakeholders interested in cyclophosphamide.

---

Overview of Cyclophosphamide

Property	Details
Chemical Class	Alkylating agent
Approved Indications	Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, leukemia, autoimmune disorders, nephrotic syndrome
FDA Approval Date	1959
Current Patent Status	Patent expired globally; some formulations have exclusivity rights in specific regions (e.g., orphan drug designations or pediatric extensions)

Source: U.S. Food and Drug Administration

---

Market Dynamics

1. Market Size & Segmentation

Segment	Approximate Market Share (2022)	Notes
Oncology (cancer treatment)	70%	Hodgkin’s lymphoma, non-Hodgkin’s, leukemia
Autoimmune & transplant	30%	Autoimmune diseases, immunosuppression

| Global Market Size (2022) | USD 250–300 million | Expected CAGR 2-3% (2023–2028) |

Sources: Market Research Future, Grand View Research

2. Patent and Regulatory Landscape

• Patent Expiration Timeline:
  Most proprietary patents expired post-2015, opening market for generics.
• Orphan Drug & Pediatric Exclusivity:
  Certain formulations retain exclusivity due to orphan designations, affecting entry barriers.
• Regulatory Challenges:
  Stringent biosimilar and generic approval pathways influence market competition.

3. Competitive Landscape

Players	Status	Market Position
Pfizer, Bristol-Myers Squibb	Generics, biosimilars	Key generic suppliers post-patent expiry
Teva Pharmaceutical Industries	Generics	Significant market share in generics
Mylan (now part of Viatris)	Generics	Broad distribution network, price competition

---

Financial Trajectory & Investment Scenarios

1. Revenue Projections (2023–2028)

Year	Estimated Revenue (USD million)	Growth Rate	Notes
2023	220–250	—	Stabilized post-patent expiry
2024	215–245	-2% to 0%	Generic competition intensifies
2025	210–240	-2% to 0%	Potential entry of biosimilars
2026	205–235	-2% to 0%	Market saturation persists
2027	200–230	-1.5% to 0%	Alternative therapies gaining ground
2028	195–225	-1.5% to 0%	Pricing pressures continue

Assumptions include normal generic penetration, minimal new formulations.

2. Investment Outlook

Scenario	Details	Implication
Conservative	No innovation, market stagnation, revenue decline	Limited upside; focus on cost management
Moderate	Introduction of biosimilars, market sharing stabilizes	Marginal decline; steady cash flow
Aggressive	Development of novel formulations or combinations	Potential for revenue stabilization or growth

3. Factors Impacting Financial Trajectory

Factor	Impact	Mitigation Strategy
Patent expiry & generic entry	Revenue erosion	Diversification into combination therapies, new indications
Regulatory hurdles	Approval delays or restrictions	Engagement with regulators, compliance investment
Competition from newer agents	Price competition, market share erosion	Enhanced clinical positioning, value-added formulations
Healthcare policy and reimbursement	Reimbursement levels, formulary inclusion	Early engagement with payers, demonstrating value

---

Market Drivers & Challenges

Key Drivers

• Established Clinical Efficacy:
  Recognized in lymphoma and autoimmune disorder treatments, ensuring steady demand.

• Patent Expiration Benefits:
  Cost reductions due to generics increase accessibility and volume.

• Expanding Global Access:
  Emerging markets offer growth opportunities for cost-effective formulations.

Key Challenges

• Emerging Therapies:
  Immunotherapies and targeted agents increasingly replace traditional chemotherapeutics.

• Pricing & Cost Containment:
  Governments and payers enforce strict price controls, pressuring margins.

• Regulatory Stringency:
  Biosimilar and bioequivalence approvals require clinical data, lengthening timelines.

---

Comparison with Similar Oncology Drugs

Drug	Market Size (2022, USD millions)	Patent Status	Growth Outlook
Cyclophosphamide	250–300	Expired (post-2015)	Moderate, stable, declining
CHOP regimen components*	1,500+ (collectively)	Varies	Steady, but declining with newer agents
Rituximab	4,000+	Patent expired in many jurisdictions	Stable, but facing biosimilars

*Note: CHOP includes cyclophosphamide, doxorubicin, vincristine, prednisolone.

---

Regulatory & Policy Environment

Region	Key Policies	Impact on Investment
United States	FDA biosimilar pathway, orphan drug incentives	Opportunities via orphan designations
European Union	EMA biosimilar guidelines, centralized approval processes	Accelerates generic entry, increases competition
Emerging Markets	Varied regulatory standards, high demand for affordable options	Growth potential; less stringent approval processes

---

Opportunities and Risks

Opportunities	Risks
Expansion into untapped markets (Asia, Africa)	Market saturation post-generic entry
Developing combination therapies or new indications	Regulatory delays or rejections
Leveraging orphan drug status for select formulations	Pricing pressures, reimbursement hurdles
Strategic partnerships and licensing agreements	Quality control concerns with generics

---

Key Considerations for Investors

• Patent Landscape:
  Expect revenue decline post initial patent expiration; focus on differentiation strategies.

• Pipeline & Innovation:
  Minimal proprietary pipeline; potential value in reformulations or combination therapies.

• Market Trends:
  Shift towards targeted therapies and immunotherapies may diminish reliance on chemotherapeutic agents.

• Pricing & Reimbursement Policies:
  Increasing affordability pressures in global markets could compress margins.

---

Key Takeaways

• Cyclophosphamide remains a valuable, volume-driven pharmaceutical agent with a well-established clinical profile.
• The post-patent environment is characterized by a transition to generic competition, leading to revenue decline.
• Market growth prospects are limited but stable, with opportunities in emerging markets and orphan drug niches.
• Investment strategies should focus on diversifying within the broader oncology portfolio, leveraging regulatory pathways, or developing innovative formulations.
• The competitive landscape is intensified by biosimilars, alternative treatments, and evolving healthcare policies.

---

FAQs

1. How will patent expirations impact cyclophosphamide's market revenue?
Patent expirations primarily led to heightened generic competition, reducing prices and margins. Revenue is expected to decline approximately 2-3% annually post-2015, stabilizing at lower levels due to volume sales.

2. Are there opportunities for branded formulations to maintain profitability?
Yes. Formulations with orphan drug designations or pediatric exclusivity can sustain some market share, especially in niche indications. Developing combination products may also offer differentiation.

3. How does the rise of targeted therapies affect cyclophosphamide?
Targeted therapies and immunotherapies are often preferred over traditional chemotherapeutics due to improved safety profiles and efficacy. This trend may further reduce cyclophosphamide’s market share in certain indications but leaves room in low-cost, volume-driven settings.

4. What are the main regulatory hurdles for cyclophosphamide?
Generic approval pathways are well-defined, but biosimilar development requires demonstrating bioequivalence and safety. Regulatory approval variability across regions influences market entry timelines.

5. Is there growth potential in emerging markets?
Yes. Cost-sensitive regions, such as Asia-African countries, present significant growth opportunities due to increased access to affordable chemotherapeutic agents, provided quality standards are maintained.

---

References

1. FDA. Cyclophosphamide approvals and prescribing information. [2022].
2. Grand View Research. Global Oncology Drugs Market Forecast (2022–2028).
3. Market Research Future. Chemotherapeutic Agents Market Analysis.
4. European Medicines Agency. Guidelines on biosimilar medicines.
5. EvaluatePharma. Oncology pipeline and market analysis.